Bayer (BAYGn.DE), Germany’s largest pharmaceutical, will focus on neurology, rare disorders, and immunology instead of women’s health.
“When it comes to research and the ensuing clinical stages, we will no longer have a particular focus on women’s health,” Bayer’s pharmaceuticals unit chief Stefan Oelrich told Reuters on Friday. However, Bayer, producer of Yasmin birth-control pills and the Mirena intrauterine device, said it would continue to explore non-hormonal menopausal symptoms alleviation elinzanetant as one of its four most promising pharmaceutical candidates.
Bayer’s June leadership transition prompted the adjustment. New CEO Bill Anderson will face thousands of lawsuits alleging Roundup weedkiller causes cancer, an underperforming medicinal development pipeline, and dissatisfied investors seeking a strategy overhaul.
In a statement, Bayer stated it would study medications for cancer, cardiovascular disease, neurology, uncommon disorders, and immunology after acquiring Schering Pharma’s major women’s health business in 2006.
Oelrich stated that neurology, uncommon disorders, and immunology had gained prominence due to recent cell and gene therapy partnerships.
He said Bayer’s medicinal work had fallen short, but immunology research might yet deliver women’s health goods.
